Breast cancer in moroccan young women: A retrospective study

被引：14
作者：
Abahssain H. [1 ]
Lalya I. [2 ]
El M'Rabet F.Z. [3 ]
Ismaili N. [1 ]
Razine R. [4 ]
Tazi M.A. [5 ]
M'Rabti H. [1 ]
El Mesbahi O. [3 ]
Benjaafar N. [2 ]
Abouqal R. [4 ]
Errihani H. [1 ]
机构：
[1] Department of Medical Oncology, National Institute of Oncology, Rabat
[2] Department of Radiotherapy, National Institute of Oncology, Rabat
[3] Department of Medical Oncology, Hassan II University Hospital, Fez
[4] Laboratory of Biostatistics, Epidemiology and Clinical Research, Rabat
[5] Epidemiology Unit, National Institute of Oncology, Rabat
来源：
BMC Research Notes | / 3卷 / 1期
关键词：
Breast Cancer; Overall Survival; Docetaxel; Trastuzumab; Inflammatory Breast Cancer;
D O I：
10.1186/1756-0500-3-286
中图分类号：
学科分类号：
摘要：
Background. Breast cancer is uncommon in young women and induces more aggressive biologic characteristics. Survival in young women has been widely studied in developed countries. Less favorable prognosis and low survival were found. In Morocco, this study is the first investigation of clinical features, treatment and prognosis associated with breast cancer in young women. Findings. Four hundred and nine women aged 35 years or less were included in this study. All these women were diagnosed as having breast cancer at the National Institute of Oncology in Rabat, Morocco between 2003 and 2007. The relation between clinical and therapeutic characteristics and event-free survival (EFS) and overall survival (OS) were assessed by Cox regression analysis. The median age of the patients was 32 years. Fifty three patients (13%) have metastatic disease at diagnosis and 356 patients (87%) had localised disease. In 57.9% of the cases, the estrogen receptors status was positive. The median follow-up was 32.2 months. After 3 years the survival rate was 80.6%. In the case of localised disease, OS and EFS at 3 years were 83.2% and 62.5%, respectively. OS and EFS at 3 years was higher in patients with stage I than patients with stage II and stage III (p = 0.001). Positive estrogen receptors was significantly associated to OS and EFS at 3 years compared to negative estrogen receptors (p = 0.001). Adjuvant chemotherapy, adjuvant radiotherapy and adjuvant hormone therapy were associated with net benefit in OS and EFS at 3 years. Cox regression analysis showed that negative ER was significantly associated with poorer OS (HR = 2.42, 95% CI = 1.25 - 4.66, p < 0.009) and poorer EFS (HR = 1.73, 95%CI = 1.05 - 2.86, p = 0.03). Stage III disease were associated to poorer EFS (HR = 5.35, 95%CI = 1.60 -17.84, p = 0.006). Conclusions. In Morocco, young women with breast cancer had less favorable prognosis. Multivariate analysis showed that negative hormone receptor status was associated with lower EFS and OS. Clinical trials should be launched to improve the survival of these young women with breast cancer. © 2010 Abahssain and Ismaili et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 30 条
[1]  
Merrill R.M., Capocaccia R., Feuer E.J., Mariotto A., Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) program, Int J Epidemiol, 29, pp. 197-207, (2000)
[2]  
Bland K.I., Menck H.R., Scott-Conner C.E., Morrow M., Winchester D.J., Winchester D.P., The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States, Cancer, 83, pp. 1262-1273, (1998)
[3]  
Axelrod D., Smith J., Kornreich D., Grinstead E., Singh B., Cangiarella J., Guth A.A., Breast cancer in young women, J Am Coll Surg, 206, 3, pp. 1193-203, (2008)
[4]  
Adami H.-O., Malker B., Holmberg L., The relation between survival and age at diagnosis in breast cancer, New England Journal of Medicine, 315, 9, pp. 559-563, (1986)
[5]  
Chung M., Chang H.R., Bland K.I., Wanebo H.J., Younger women with breast carcinoma have a poorer prognosis than older women, Cancer, 77, 1, pp. 97-103, (1996)
[6]  
Walker R.A., Lees E., Webb M.B., Dearing S.J., Breast carcinomas occurring in young women ( 35 years) are different, Br J Cancer, 74, pp. 1796-1800, (1996)
[7]  
Xiong Q.H., Valero V., Kau S.W., Et al., Female patients with breast carcinoma age 30 years and younger have a poor prognosis - The M. D. Anderson Cancer Center Experience, Cancer, 92, pp. 2523-2528, (2001)
[8]  
Thuerlimann B., International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland, Breast Cancer, 8, pp. 294-297, (2001)
[9]  
Chevallier B., Chollet P., Merrouche Y., Roche H., Fumoleau P., Kerbrat P., Genot J.Y., Fargeot P., Olivier J.P., Fizames C., Clavelt M., Yver A., Chabernaud V.C., Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer, J Clin Oncol, 13, pp. 1564-71, (1995)
[10]  
Winchester D.P., Osteen R.T., Menck H.R., The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age, Cancer, 78, 8, pp. 1838-1843, (1996)
123